Lipid-lowering drug use in Italian primary care: Effects of reimbursement criteria revision

European Journal of Clinical Pharmacology

Volumn 64, Issue 6, 2008, Pages 619-625

  Trifiro G ^a,d   Alacqua, M ^a   Corrao, S ^b   Moretti, S ^c   Tari, D U ^c   Galdo, M ^c   Caputi, A P ^a,d   Arcoraci, V ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Caserta 1 Local Health Service   (Italy)

^d IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

General practice; Lipid lowering drug; Omega 3 fatty acids; Prevalence of use; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CALCULATION; CONFIDENCE INTERVAL; DATA BASE; DRUG USE; GENERAL PRACTICE; GENERAL PRACTITIONER; HEART INFARCTION; HUMAN; ITALY; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REIMBURSEMENT;

EID: 42549133700     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0459-1     Document Type: Article

References (30)

1. Gotto AM, Grundy SM (1999) Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, 9th Council Meeting. Circulation 99:E1-E7
2. Hebert PR, Gaziano JM, Chan KS, Hennekens CH (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278:313-321
3. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT investigators (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158
4. Bellosta S, Paoletti R, Corsini A (2004) Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109:III50-III57
5. Din JN, Newby DE, Flapan AD (2004) Omega 3 fatty acids and cardiovascular disease-fishing for a natural treatment. BMJ 328:30-55
6. Agenzia Italiana del farmaco (AIFA) (2004) L'uso dei farmaci in Italia. Rapporto OsMed 2004. http://www.agenziafarmaco.it/edi_osmed_2004.html. Accessed 15 Apr 2007
7. Agenzia Italiana del Farmaco (AIFA) (2004) Revisione delle Note CUF. http://www.agenziafarmaco.it/new16_05112004.html. Accessed 15 Apr 2007
8. Lawrenson R, Williams T, Farmer R (1999) Clinical information for research: the use of general practice databases. J Pub Health Med 21:299-304
9. Piacentini N, Trifiró G, Tari M, Moretti S, Arcoraci V, UVEC group (2005) Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol 61:615-620
10. Trifiro G, Corrao S, Alacqua M, Moretti S, Tari M, Caputi AP, Arcoraci V, UVEC Group (2006) Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br J Clin Pharmacol 62:582-590
11. Trifiro G, Barbui C, Spina E, Moretti S, Tari M, Alacqua M, Caputi AP, UVEC group, Arcoraci V (2006) Antidepressant drugs: prevalence, incidence and indication of use in general practice of southern Italy during the years 2003-2004. Pharmacoepidemiol Drug Saf 16:552-559
12. Palmieri L, Panico S, Vanuzzo D, Ferrario M, Pilotto L, Sega R, Cesana G, Giampaoli S, Gruppo di Ricerca del Progetto CUORE (2004) Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score. Ann Ist Super Sanita 40:393-399
13. Ferrario M, Chiodini P, Chambless LE, Cesana G, Vanuzzo D, Panico S, Sega R, Pilotto L, Palmieri L, Giampaoli S, CUORE Project Research Group (2005) Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol 34:413-421
14. Walley T, Folino-Gallo P, Stephens P, Van Ganse E (2005) Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 60:543-551
15. Deambrosis P, Saramin C, Terrazzani G, Scaldaferri L, Debetto P, Giusti P, Chinellato A (2007) Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol 63:197-203
16. Isles CG, Hole DJ, Hawthorne VM, Lever AF (1992) Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet 339:702-706
17. Savoie I, Kazanjian A (2002) Utilization of lipid-lowering drugs in men and women. A reflection of the research evidence? J Clin Epidemiol 55:95-101
18. DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG (2003) Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 89:417-421
19. Ko DT, Mamdani M, Alter DA (2004) Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 291:1864-1870
20. LaRosa JC, He J, Vupputuri S (1999) Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282:2340-2346
21. Leiter LA (2005) Diabetic dyslipidaemia: effective management reduces cardiovascular risk. Atheroscler Suppl 6:37-43
22. Vijan S, Hayward RA, American College of Physicians (2004) Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 140:650-658
23. Florentinus SR, Heerdink ER, Klungel OH, de Boer A (2004) Should rosuvastatin be withdrawn from the market? Lancet 364:1577
24. Kozyrskyj A, Raymond C, Racher A (2007) Characterizing early prescribers of newly marketed drugs in Canada: a population-based study. Eur J Clin Pharmacol 63:597-604
25. [No authors listed] (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354:447-455
26. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, Third Joint Task Force of European and Other Societies on Cardiovascular Disease and Prevention in Clinical Practice (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 170:145-155
27. Autier P, Creplet J, Vansant G, Brohet C, Paquot N, Muls E, Mullie P, Grivegnee AR (2003) The impact of reimbursement criteria on the appropriateness of 'statin' prescribing. Eur J Cardiovasc Prev Rehabil 10:456-462
28. Jones G (2003) Prescribing and taking medicines. BMJ 327:819
29. Agenzia Italiana del farmaco (AIFA) (2005) L'uso dei farmaci in Italia. Rapporto OsMed 2005. x http://www.agenziafarmaco.it/edi_osmed_2005.html. Accessed 15 Apr 2007
30. Brasesco P, Stimamiglio A, Canepa A, Ghia M, Comaschi M, Bistolfi L, Valle I, Cordano C (2006) La prescrizione di statine in medicina generale. Ricerca nell'ASL-3 Genovese. SIMG 6:18-20. http://www.simg.it/servizi/ servizi_riviste2006/06_2006/4.pdf. Accessed 1 May 2007